The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patterns of maintenance treatment (Tx) following first-line bevacizumab (bev) plus chemotherapy (CT) for metastatic colorectal cancer (mCRC): Results from a large German community-based cohort study.
Dirk Arnold
Disclosure not yet available
Volker Petersen
Disclosure not yet available
Manfred Kindler
Disclosure not yet available
Mathias Schulze
Disclosure not yet available
Jorg Seraphin
Disclosure not yet available
Axel Hinke
Disclosure not yet available
Stefanie Srock
Disclosure not yet available
Andreas Kutscheidt
Disclosure not yet available